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Abstract
Protein aggregates in the brain play a central role in cognitive decline and structural damage
associated with neurodegenerative diseases. For instance, in Alzheimer’s disease the formation
of Amyloid-beta plaques and tau proteins neurofibrillary tangles follows from the accumulation
of different proteins into large aggregates through specific mechanisms such as nucleation and
elongation. These mechanisms have been studied in vitro where total protein mass is conserved.
However, in vivo, clearance mechanisms may play an important role in limiting the formation of
aggregates. Here, we generalize classical models of protein aggregation to take into account both
production of monomers and the clearance of protein aggregates. Depending on the clearance
model, we show that there may be a critical clearance value above which aggregation does not
take place. Our result offers further evidence in support of the hypotheses that clearance mech-
anisms play a potentially crucial role in neurodegenerative disease initiation and progression;
and as such, are a possible therapeutic target.
1 Introduction
Alzheimer’s disease (AD), and other related neurodegenerative diseases, are associated with the
assembly of specific, toxic proteins into fibrillar aggregates. Alzheimer’s disease, in particular, is
characterized by the aggregation of Amyloid-β (Aβ) plaques and tau protein neurofibrillary tangles
(NFT). The role of Aβ in Alzheimer’s is thought to be so central to the disease that it is the basis
of the so-called ‘Amyloid-β hypothesis’ [1, 2, 3], stating that that the accumulation and deposition
of oligomeric or fibrillar amyloid beta peptide is the main cause of the disease. This hypothesis
has provided a guide for most of AD research over the last 20 years. However, recent experimental
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evidence, and the failure of several drug trials, has lead to renewed scrutiny of this foundational
assumption.
The production of Aβ is a natural process related to neuronal activity. Indeed, Aβ is a nor-
mal metabolic waste byproduct [4, 5] that is typically removed from intracellular and extracellular
compartments by several clearance mechanisms [6, 7]. In healthy subjects waste proteins are bro-
ken down by enzymes, removed by cellular uptake, or efflux to cerebrospinal fluid compartments
where they eventually reach arachnoid granulations, or lymphatic vessels. While healthy clearance
mechanisms, working in harmony, avert the buildup of toxic Aβ plaques and tau NFT; their im-
pairment or dysfunction can lead to toxic levels of aggregates [7]. The specifics of in-vivo clearance
mechanisms remain a topic of clinical debate; however, the kinetics enabling proteins to amass into
toxic aggregates can be carefully, and systematically, studied in vitro and under varied conditions.
The production of Aβ, at a high level, is mediated by a membrane protein called amyloid precursor
protein (APP). APP is typically cleaved by α-secretase and the resulting products do not aggre-
gate. However, APP can also be cleaved by β-secretase, which results in soluble monomeric APP
fragments of different sizes. The most common size categories are Aβ38, Aβ40, and Aβ42. While
monomeric Aβ38 is not prone to further aggregation; Aβ40 and Aβ42, containing two additional
amino acids at the C terminus, are the main isoforms of interest in the study of AD pathology.
Protein aggregation pathways are, in general, complex and involve multiple steps. In fact, it has
recently been shown [8] that the aggregation properties of Aβ40, which is more abundant, differ from
those of the more aggregate-prone Aβ42; even under the same conditions. A theoretical framework
of chemical kinetics and aggregation theory [9, 10, 11] has been combined with careful, systematic
in vitro experiments performed under differing conditions; such as varied concentration or pH.
This approach has: elucidated effective pathways and mechanisms for nucleation, aggregation and
fragmentation [12]; and produced a deep understanding of key properties, underlying the formation
of aggregates under ideal conditions, with the potential for therapeutic intervention [13, 14].
Here, we develop a mathematical framework to describe the effects of clearance and monomer
production chemical kinetics driving aggregation; we apply the framework to the study of Aβ. To
accomplish this, we extend the current theory describing Aβ aggregation in vitro, which has been
validated against experiment, to include monomer production and oligomer clearance terms. In
particular, we study two different clearance mechanisms: one where total mass is conserved (size-
independent clearance); and one where it is not (size-dependent clearance). In the former case we
show the full system reduces to three equations amenable to a systematic analysis. We identify a
critical value of clearance above which the production of toxic aggregates does not take place. Our
results offer further evidence in support of two main hypotheses: that clearance mechanisms play
a crucial role in neurodegenerative disease initiation and progression; and that therapies enhancing
clearance above a prescribed, critical value may serve as a possible intervention strategy. In partic-
ular, we will exhibit the existence of critical clearance values; such values are consistent with the
observation of disease onset when natural clearance mechanisms within the brain have degraded
through aging.
2 A model of toxic protein aggregation
Our model for protein aggregation-dynamics model includes multiple mechanisms: heterogeneous
primary nucleation; homogeneous primary nucleation; secondary nucleation; linear elongation; frag-
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mentation; and clearance (c.f. Fig. 1). These mechanisms lead to a general class of mathematical
models that can describe a wide range of aggregating systems in vitro. In particular, by includ-
ing heterogeneous primary nucleation terms, a source term for new nuclei, that is independent of
monomer concentration, is present; this source is in addition to the usual monomer-dependent ho-
mogeneous primary nucleation. Thus, in such a model, the importance of interfaces in the initiation
of nucleation is sufficiently accounted for. In the model, each aggregate of a given size is represented
by a population. In general, each population, with aggregates of size i, will be represented by an
indexed concentration; we use the special notation m(t) for the monomer population i = 1, while
all other aggregate concentrations are denoted by pi(t) for i ∈ {2, 3, . . . }. The master equations are
then:
dm
dt
= γ − λ1m− 2k0 − ncknmnc − 2k+mP − n2k2σ(m)M + 2koff P (1)
dp2
dt
= −λ2p2 + k0 + δ2,ncknmnc − 2k+mp2 + δ2,n2k2σ(m)M + 2koff p3 (2)
dpi
dt
= −λipi + δi,ncknmnc + 2k+m(pi−1 − pi) + 2koff(pi+1 − pi) + δi,n2k2σ(m)M, i > 2,(3)
where δi,j is Kronecker’s delta (1 if i = j and 0 otherwise) and
σ(m) =
mn2KM
KM +mn2
, P =
∞∑
i=2
pi, M =
∞∑
i=2
ipi. (4)
Here, P and M are the first two moments of the population distribution; they represent the total
number and total mass of aggregates, respectively. In these equations, the parameters represent
the following effects, sketched in Fig. 1: γ: (constant) monomer production such as by β-secretase
mitigated cleavage of APP, driving mass influx; λi: clearance of aggregate of size i such as by
lymphatic or cellular processes; k0: heterogeneous primary nucleation (independent of the monomer
concentration); kn and nc: nucleation of aggregates of size nc > 1; k+: linear elongation transforming
aggregate from size i to i+1; k2: secondary nucleation of aggregates of size n2 > 1; KM : saturation
of the secondary nucleation; koff: depolymerization by one monomer.
The aggregation model (1)-(3), and its many variations, have served as a template for in vitro
experiments [8, 13, 15]. Multiple experimental fittings have shown that the exponents nc and n2
are: nc = n2 = 2 for Aβ40 and for Aβ42 in the presence of a PBS buffer [8, 15]; for Aβ42 in
the presence of a HEPES buffer n2 = 2 and nc = 0 provides the best fit [13]. For the discussions
and derivations in this manuscript we take the view of PBS buffer experiments [8, 15] so that
nc = n2 = 2. Adaptation to Aβ42 HEPES, so that nc = 0, is straightforward and all numerical
results are qualitatively similar. When fitting experimental data it is often the case that only one of
k0 or kn, depending on the best data fit, is used; i.e. that either heterogeneous primary nucleation
or homogeneous primary nucleation best explains the particular experimental data.
The primary purpose of this manuscript is to describe the qualitative impact of clearance mech-
anisms in the dynamics and a particular choice of nucleation mechanism, i.e. k0 = 0 versus kn = 0,
does not affect the results. Examples of fitted Aβ model parameters are listed in Table 1. PBS
and HEPES refer to the buffers used in the corresponding experiments. Aggregation, in the fitted
experiments, proceeds much faster than depolymerization and koff = 0 is found to be a good fit to
describe the dynamics. However, from a theoretical point of view, we note that koff = 0 implies that
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Figure 1: Mechanisms included in the master equations (1)-(3). We consider multiple effects for
the formation of aggregates into our systems with rates constants ki. The constants corresponding
to transfer of mass to and from the external system are represented by greek letters (γ and λi).
The process of heterogeneous nucleation (with constant k0) is similar to homogeneous primary
nucleation and is not depicted (the main difference being that its rate does not depend on the
monomer concentration).
there is no non-vanishing stationary distribution in the absence of clearance and production terms.
Here, we will first follow experimental data and take koff = 0. Then, we will show that the addi-
tion of this small term does not change our results. Therefore, we will use the fitted experimental
parameters given in Table 1. Clearance and production have not been investigated experimentally;
thus, we leave them as free parameters. In particular, we will be interested in determining particular
values of these parameters when a qualitative change of the dynamics occurs.
3 Size-independent clearance
In the case of size-independent clearance, we have λi = λ > 0 for all i. Our main question is
to understand the role of the clearance term. In particular, we will establish that if clearance is
sufficiently large, the formation of aggregates does not take place.
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Table 1: Typical parameters for the Aβ model. PBS and HEPES refer to the buffer used for the
experiments. Note that Aβ42 is generally faster than Aβ40 and HEPES buffer is faster than PBS.
In these experiments, aggregation is sufficiently fast so that koff = 0 provides a good fit. The values
of λcrit give the critical values of clearance and their approximations for the size-independent case
(see text). The values of τ1 and τ2 give the typical time scales associated with each dynamics (see
text).
param. mechanism Aβ40 PBS [15] Aβ42 PBS [8] Aβ42 HEPES [16] units
k0 heterogeneous nucleation 0 0 1.6× 10−11 Mh−1
kn homogeneous nucleation 5.8× 10−3 1.2× 10−1 0 M1−nch−1
nc homogeneous nucleation 2 2 2 unitless
k2 secondary nucleation 1.1× 107 3.6× 107 2.1× 1014 M−2h−1
n2 secondary nucleation 2 2 2 unitless
KM saturation 3.6× 10−11 3.6× 10−12 2.3× 10−17 M2
k+ elongation 1.1× 109 1.1× 1010 1× 1010 M−1h−1
koff depolymerization 0 0 0 h−1
m0 Initial monomer c. 3× 10−6 3× 10−6 3× 10−6 M
λcrit critical clearance 0.72 2.45 17.0 h−1
λ˜crit perfect bifurcation 0.72 2.47 17.0 h−1
α nonlinear coefficient 312,042 647,390 2.83726×106 M−1 h−1
τ1 exponential time scale 1.4 0.4 0.06 h
τ2 amplification time scale 12.6 2.5 0.4 h
λ
(1)
crit critical clearance ν = 1 7.8×10−5 9.2×10−5 4.8×10−3 h−1
λ
(0)
crit critical clearance ν = 0 0.72 2.47 17.0 h
−1
λ
(−1)
crit critical clearance ν = −1 13.2×103 13.2×104 12×104 h−1
3.1 Moment analysis
In the size-independent case, a well-known but remarkable feature of the system (1)-(3) is that a
closed system of equations for the first two moments P and M and the monomer concentration
m = p1 can be obtained exactly:
dP
dt
= − λP + k0 + knm2 + k2 σ(m)M, (5)
dM
dt
= − λM + 2k0 + 2(k+m− koff)P + 2knm2 + 2k2 σ(m)M, (6)
dm
dt
= γ − λm − 2k0 − 2(k+m− koff)P − 2knm2 − 2k2 σ(m)M, (7)
where σ(m) = m2KM/(KM +m2) and we have chosen n2 = 2. The total mass of the system
Mtot = M +m satisfies, by summing (6)-(7), the evolution equation
dMtot
dt
= −λMtot + γ. (8)
This equation implies that the total mass in the system evolves to a stable steady state Mtot = γ/λ
with a typical time-scale 1/λ. To simplify the analysis, we will further assume that, initially, the
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system is at this state by choosing the following unseeded initial conditions
M(0) = P (0) = 0, m(0) = m0 = γ/λ, (9)
and the total mass of the system is conserved for all time Mtot(t) = m0. The term ‘unseeded’ refers
to the fact that, initially, there is no toxic protein in the system (hence, no seed). This condition
assumes a lack of aggregated species in a healthy in vivo state. Indeed, it is observed that soluble
Aβ monomers are found in healthy individuals of all ages while aggregates larger than monomers
are correlated with Alzheimer’s disease progression [17]. An extra advantage of this approach is
that it fixes the constant γ = m0λ.
Before we study the system in full generality, it is useful to consider the overall dynamic of
the system for a typical set of parameters for the aggregation of Aβ40 given in the first column of
Table 1. We will use this set of parameters for all our examples. The other data sets are qualitatively
equivalent and the values of various derived quantities are given in Table 1. As shown in Fig. 2,
the typical behavior of the system from an unseeded initial condition is for the toxic protein mass
to increase up to finite value M∞ while the monomer concentration decreases to m∞ in a typical
sigmoid-like behavior. We observe that, in the absence of clearance, the monomer population is
Figure 2: Typical dynamics of the monomer (blue) and toxic (red) concentration (in moles) for
different values of the clearance (λ in h−1) for Aβ40 with parameters from Table 1 and λ = 0 (large
dashed), λ = 0.2 (solid) and λ = 1 (small dashed). Asymptotic values for λ = 0.2 are shown with
dotted lines.
completely converted to toxic proteins (λ = 0, dashed curves in Fig. 2). Conversely, for large
clearance almost no conversion takes place (λ = 1, dotted curves in Fig. 2). Some of the monomers
are converted (solid curves for λ = 0.2 in Fig. 2) for the case of moderate clearance. Of particular
interest for our discussion is the change of behavior at some critical value λcrit of the clearance λ
where aggregation becomes negligible.
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To derive an exact value for λcrit, we determine the dependence of the asymptotic states m∞ on
λ. Using the steady state hypothesis with m = m∞, P = P∞ andM = M∞ in (5)-(6) one expresses
the latter two states as a function of the parameters, λ and m∞. These relations are substituted in
(7) to produce the implicit equation q(λ,m∞) = 0 with
q(m∞, λ) = 2k+knm5∞ −m4∞ (2k+k2KM − 2λkn + 2knkoff)
−m3∞
(−λ2 − 2k+k2m0KM + 2k2λKM − 2k+knKM − 2k2koffKM − 2k+k0)
−m2∞
(−2k0λ−2k2λm0KM + 2k2m0koffKM −2λknKM + 2knkoffKM + 2k0koff +λ2m0)
+m∞
(
λ2KM + 2k+k0KM
)
+ 2λk0KM − 2k0koffKM − λ2m0KM
(10)
For instance, for the same parameter values as in Fig. 2, we show in Fig. 3 the values of m∞ as
a function of λ. We observe a sharp transition for a critical value of the clearance parameter λ.
Figure 3: Perfect (red) and imperfect (blue) transcritical bifurcation obtained for Aβ40. Unstable
(dashed) and stable(solid) equilibrium solutions. In this case, we have λ˜crit ≈ 0.72 and m˜∞ ≈
0.7 + 3.2λ˜. Dashed curves indicate unstable equilibria solutions and solid curves denote stable
equilibria.
There are three necessary conditions for λcrit: first that λcrit is non-negative; second that m∞ is
maximal; and third that the value of m∞ coincides with m0. The last two conditions can be realized
by computing the derivative of the expression q(λ,m∞) = 0 evaluated at m = m∞. Therefore, λcrit
is given by the positive root of L(λ) = 0 where
L(λ) =
∂q
∂m∞
∣∣∣∣
m∞=m0
= −4koffKMm∞ (k2m0 + kn) + 6k+knKMm2∞ + 6k2koffKMm2∞ − 8k+k2KMm3∞
+ 6k+k2m0KMm
2
∞ + 2k+k0KM − 8knkoffm3∞ + 10k+knm4∞ − 4k0koffm∞ + 6k+k0m2∞
+ λ
(
4KMm∞ (k2m0 + kn)− 6k2KMm2∞+ 8knm3∞+ 4k0m∞
)
+ λ2
(
KM + 3m
2
∞− 2m0m∞
)
(11)
For Aβ-40 the critical clearance, as shown in Fig. 3, is λcrit = 0.72. Critical clearance rates for the
other experimental data sets are given in Table 1 for comparison.
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3.2 Bifurcation and normal form analysis
In a neighborhood of λcrit, m∞, as a function of λ, undergoes a sharp transition. This transition is
not a bifurcation in the strict sense but, in the parlance of dynamical systems, it can be described as
an imperfect transcritical bifurcation when heterogeneous nucleation and homogeneous nucleation
terms can be understood as an imperfection and are sufficiently small with respect to the elongation.
More specifically, when k0/(k+m20) 1 and kn/k+  1 the system is well approximated by k0 = 0
and kn = 0. In this limiting case, the fixed point (P,M,m) = (0, 0,m0) for the system (5)-
(7) undergoes a (perfect) transcritical bifurcation at λ˜crit ≈ λcrit that can be obtained by locally
expanding m∞ in λ to find
m˜∞ = m0 +
1
α
(λ− λ˜crit) +O
(
(λ− λ˜crit)2
)
, (12)
where λ˜crit is specified by the formula
λ˜crit =
m0
(√
k2KM
(
m0 (k2m0 + 2k+)KM − 2koffKM + 2m20 (k+m0 − koff)
)
+ k2m0KM
)
KM +m20
, (13)
and α is defined by the expression
α =
m0
(
k2KM
(
2λ˜crit + 3k+m0 − 2koff
)
− λ˜2crit
)
λ˜crit
(
KM +m20
)− k2m20KM . (14)
When the clearance is close to the critical value the linear approximation to the perfect bifurcation
is a reasonable approximation for the imperfect bifurcation as can be appreciated in Fig. 3 where
λ˜crit ≈ 0.72 and m˜∞ ≈ 0.7 + 3.2λ˜. By analogy with epidemiology we define a dimensionless
neurodegenerative reproduction number
R0 =
λ˜crit
λ
, (15)
such that for R0 < 1 the protein toxic level is negligible and grows to finite value for R0 > 1.
The existence of a critical clearance rate shows that in the healthy regime, i.e. for sufficiently
large values of clearance, the system (1)-(3) with size-independent clearance can support a small,
endemic, population of toxic proteins. The aggregation of a significant toxic population, in this
case, occurs only when the system’s clearance rate, λ, drops sufficiently below the critical clearance
rate λcrit. We can explore the dynamics close to the bifurcation by considering the normal form of
the system for the perfect system ((5)-(7) with k0 = kn = 0) near λ = λ˜crit. The general method to
obtain the normal form of a transcritical bifurcation for an arbitrary smooth vector field is given in
Appendix A. Applying these ideas, we can approximate the full system by
P˙ = −(λ− λ˜crit)P + α
vP
P 2, (16)
M˙ = −(λ− λ˜crit)M − αM2, (17)
m˙ = −(λ− λcrit)(m−m0) + α(m−m0)2, (18)
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Figure 4: Toxic mass concentration M(t) as a function of time for the unseeded (black dashed)
system (5)-(7), for the perfect seeded system (neglecting homogeneous and heterogeneous primary
nucleation) (red) and the normal form approximation of M(t) (dotted blue). The initial conditions
were selected so that the initial growth rates matched the initial growth rate of the unseeded system.
Taking S = 2.4 × 10−13 to be a small seed value, the red curve was generated with unseeded
initial conditions; the black dashed curve was computed using seeded initial conditions given by
(P (0),M(0),m(0)) = (S, S/2,m0 − S); and, the blue dashed curve was generated by solving (17)
with M(0) = S/2. Parameters are for the Aβ40 values of Table 1 and λ = 1/2.
where α is given by (14) and
vP = − λ˜crit
2
(
k+m0 − koff + λ˜crit
) . (19)
Fig. 4 shows a comparison of the total toxic mass evolution, versus time, obtained for the imperfect
unseeded system, the perfect seeded system, and the normal form. As expected, the agreement is
excellent as long as the system is close enough to the bifurcation point.
3.3 Size distribution
Next, we consider the effect of clearance on size distribution. First, we take koff = 0 as suggested
by the data sets. Since, we are interested in the asymptotic size distribution, we can assume that
p1 = m∞ in Eqs. (1–3), in which case, we have simply that
pi =
2k+m∞
λ+ 2k+m∞
pi−1 = δ0pi−1, ⇒ pi = δi−20 p2, i > 2. (20)
Using the definition of M =
∑
i>1 ipi, we obtain:
p2 = M∞
(1− δ0)2
2− δ , ⇒ pi = M∞
δi−20 (1− δ0)2
2− δ0 i > 2. (21)
9
Figure 5: The effect of the parameter koff on the size distribution can be appreciated by computing
δ/δ0 as a function of koff. We see that for koff < m∞k+, the role of koff is negligible. The dashed
curves are given by the asymptotic approximation (25). Parameters are for the Aβ40 values of
Table 1 and λ = 1/2.
This analysis is not valid for λ→ 0. In that case, the total mass of the system is systematically
transferred to larger and larger particles and in the long-time limit all finite aggregate concentrations
tend to vanish and the trivial distribution is pi = pi−1 = p2 = 0. However, in that limit, the
assumption koff = 0 is not justified anymore as even a small value of koff allows for a non-trivial size
distribution. Indeed, with koff 6= 0 , we have the following reccurence relation for ci
0 = −λipi + 2k+m∞(pi−1 − pi) + 2koff(pi+1 − pi), i > 2, (22)
with a single bounded solution fo the form
pi = δ
i−2p2, i > 2. (23)
with
δ =
k+m∞
2koff
+
1
2
+
λ
4koff
− 1
2
√
(2koff + 2k+m∞ + λ) 2
4k2off
− 4k+m∞
koff
. (24)
An asymptotic expression of δ for small and large values of koff gives:
δ =
{
δ0(1− 2λkoff(2m∞k++λ)2 ) +O
(
k2off
)
, for koff < m∞k+,
δ0
2m∞k++λ
2koff
+O (k−2off ) , for koff > m∞k+. (25)
We see that unless λ = 0, the role of koff, when sufficiently small, is negligible. We conclude that
clearance (or depolymerization) is sufficient to obtain a non-degenerate size distribution.
4 Size-dependent clearance
Next, we assume that clearance of an aggregate depends on its size. In this case, there is no simple,
closed equation for the moments, as in Sec. 3, and we must study the full system. Here, we make a
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key assumption about the dependence of the clearance on the aggregate size. We assume that there
exists a critical aggregate size, N , such that all aggregates of size N , or greater, are too large to be
cleared. Explicitly, this assumption implies that λi = 0, ∀i ≥ N . We also assume that koff = 0 and
nc = n2 = 2 then (1)-(3) can be written
dM˜
dt
= −
N−1∑
i=2
λiipi + 2k0 + 2knp
2
1 + 2k+p1P + 2k2 σ(p1)M˜, (26)
dp1
dt
= λ1(m0 − p1)− 2k0 − 2knp21 − 2k+p1P − 2k2σ(p1)M˜, (27)
dp2
dt
= −λ2 p2 + k0 + knp21 − 2k+p1p2 + k2σ(p1)M˜, (28)
dpi
dt
= −λi pi + 2k+p1(pi−1 − pi). i > 2, (29)
where P =
∑∞
i=2 pi and M˜ =
∑∞
i=2 ipi. The unseeded initial conditions for this system are
p1(0) = m0, pi(0) = 0 for 2 ≤ i, M˜(0) = 0. (30)
In general, there is no guarantee of mass conservation. For instance, if λi ≤ λ1 ∀i > 2 and there
is at least one i ≥ 2 such that λi < λ1, then the overall mass of proteins will increase in time as
shown in Appendix B.
4.1 A finite super-particle system
To study the dynamics of (26)-(29), we introduce a finite system with equivalent dynamics. Here,
we follow [19] (see also [20]) and introduce a super-particle, denoted qN , which represents the
concentration of all aggregates of size greater than or equal to N :
qN =
∞∑
i=N
pi, (31)
Since λi = 0 for all i ≥ N ; we can take the limit of the partial sums of (29) to obtain
dqN
dt
=
∞∑
i=N
2k+p1(pi−1 − pi) = lim
j→∞
j∑
i=N
2k+p1(pi−1 − pi) = 2k+p1pN−1 − 2k+ lim
j→∞
p1pj . (32)
Since the monomer concentration p1, remains bounded, for any fixed time, the last term of (32)
tends to zero as j →∞ and the super particle concentration satisfies the equation
dqN
dt
= 2k+p1pN−1. (33)
We will distinguish the finite system with a super-particle from the infinite system (26)-(29) by
introducing the notation qi = pi for i < N . Defining Q =
∑N
i=2 qi, and using (33), the corresponding
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super-particle system is defined by
dM
dt
= −
N−1∑
i=2
λiiqi + 2k0 + 2knm
2 + 2k+mQ+ 2k2 σ(m)M, (34)
dm
dt
= λ1(m0 −m)− 2k0 − 2knm2 − 2k+mQ− 2k2σ(m)M, (35)
dq2
dt
= −λ2 q2 + k0 + knm2 − 2k+mq2 + k2σ(m)M, (36)
dqi
dt
= −λi qi + 2k+m(qi−1 − qi), i = 2, . . . , N − 1, (37)
dqN
dt
= 2k+mqN−1. (38)
The unseeded conditions for (34)-(38) are
m(0) = m0, qi(0) = 0, for 2 ≤ i ≤ N, M(0) = 0. (39)
For unseeded initial conditions, the dynamics of the finite system is equivalent to the infinite one
in the following sense: First note that Q˙ = P˙ ; this follows directly from the definition of Q, P and
(31). Thus, Q and P will agree, for all time. In turn, (26) and (34) coincide when the initial data
(30) and (39), respectively, are used; thus M˜(t) = M(t) in this case. Finally, by definition, pi = qi
for 2 ≤ i < N and (31)-(32) has already established that solving (38) produces qN (t) =
∑∞
i=N pi(t)
provided the initial conditions agree. The above establishes an important fact that we rely on for
the rest of the section; solving (26)-(29) with initial conditions (30) and solving (34)-(38) with initial
conditions (39) yields
m(t) = p1(t), Q(t) = P (t), M(t) = M˜(t), (40)
pi(t) = qi(t) for 2 ≤ i < N and qN (t) =
∞∑
i=1
pi(t).
We remark, however, thatM(t), defined as the solution of (34), is the total toxic mass of both (26)-
(29) and (34)-(38), due to (40), for the unseeded initial conditions (39); however, M(t) cannot be
constructed a posteriori from the knowledge of qi(t) where i = 2, 3, . . . , N in the same manner that
M˜(t) can be retrieved from the knowledge of the pi(t). That is, we haveM(t) 6=
∑N
i=2 iqi(t). Indeed,
in the closure process of reducing the full system to a finite one, we lost information regarding the
mass of individual particles making up the superparticle. Nevertheless, both the evolution of toxic
mass of the full system, as well as the size distribution (up to size N) can be obtained by studying
the finite system (34)-(38).
4.2 Toxic mass behaviour
Systems such as (26)-(29) or (34)-(38), with size-dependent clearances, do not conserve mass in
general (see Appendix B) and the toxic mass may increase with time. We study in more details the
particular choice
λi = λ/i, for i = 1, 2, . . . , N − 1, (41)
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which expresses the modeling assumption that aggregates become increasingly difficult to clear
as their size increases. An example of the dynamics of the system (34)-(38) is shown in Fig. 6.
We observe two different behaviors. Initially, up to a time τ2, the system mostly behaves like
the conservative no-clearance model (λ = 0) even for large values of clearance. This behavior is
markedly different than the one observed in Fig. 2. Second for larger times, t > τ2, the monomer
mass always decreases and the toxic mass always increases as predicted from our general analysis.
We observe that larger clearance leads to faster toxic mass creation. This is due to the fact that in
healthy homeostasis, production and clearance are balanced. Hence larger clearance implies larger
production. The question is then to understand the transition between the two regimes as well as
the small and large time behaviors of all species.
Figure 6: Toxic mass dynamics for the size-dependent clearance λi = λ/i; the monomer population
concentration (m(t), blue lines) and total toxic mass (M(t), red lines) are shown for clearance (in
h−1) rates: λ = 0 (dashed), λ = 0.2 (solid), and λ = 1 (dotted). Parameters are for the Aβ40
values of Table 1 and λ = 1/2 N = 20.
4.3 Long-time dynamics
On long time scales, i.e. long enough so that the monomer concentration begins to decrease, the
monomer production, aggregation, and nucleation processes result in an increase to subsequent toxic
species and, therefore, to the overall toxic mass M . The asymptotic behavior of the system toxic
mass M is observed to depend entirely on the production rate, γ = λm0, as
M(t) ∼
t→∞ γ t. (42)
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Figure 7: Long time (in h) concentration (in moles) dynamics of (34)-(38) (λi = λ/i, in h−1) with
N = 20 and Aβ40 parameters (Table 1, third column); curves for λ = 0.2 (solid) with asymptotic
slopes (dotted). Time runs from 0 to 5000 hours. Parameters are for the Aβ40 values of Table 1
and N = 20.
This behavior is illustrated in a log-plot in Fig. 7; the characteristic time scale, τ2, indicates the
time at which the monomer mass begins to decay. Once the asymptotic behavior of M has been
established, the equations can be balanced asymptotically by the following dynamics:
m ∼ αmt−2/3, qN ∼ αN t2/3, qi ∼ αit1/3, i = 1, . . . , N − 1, (43)
where the symbol “∼” is understood as the long-time asymptotic behavior and the αi are constants.
This asymptotic behavior shows that the super-particle dominates the long-term dynamics; thus
P ∼ qN for large times. Physically, in the long-time limit, the monomer population, renewed by
the continuous production, is quickly promoted to the super-particle through linear aggregation.
4.4 Early-time dynamics
We observe in Fig. 6 that the early-time behavior is not greatly perturbed by altering the clearance
rate. Hence, we can obtain characteristic time scales for the amplification of the toxic mass by
considering the limit λ→ 0+. In this case, the early evolution of the toxic mass is governed by the
dynamics of (5)-(7) with λ = 0. There are two characteristic time scales of importance. First, the
time scale τ1 associated with the exponential growth of the toxic mass in early time via the inverse
of the positive linear eigenvalue, µ = 1/τ1, corresponding to the linearization of (5)-(7) around the
healthy state m = m0, M = P = 0. The linear eigenvalue is given by the positive root of
µ2 + µ
(
4m0kn − 2k2m
2
0KM
KM +m20
)
− 2k+k2m
3
0KM
KM +m20
+ 4k+m
2
0kn = 0. (44)
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Second, there is a time scale τ2 where both nucleation and amplification are balanced. It is given
by the time for the linearized solution for M(t) to reach m0. Hence τ2 is the solution of
m20 =
(
m20kn + k0
) (
KM +m
2
0
)
2knKM + 2m20kn − k2m0KM
(
1− e
τ2/τ1
2
)
. (45)
For example, for the first parameter set (Aβ40) used for the figures, these times are τ1 ≈ 1.4 h and
τ2 ≈ 12.6 h. The value of τ2 is a rudimentary estimate for the time of amplification; it is a lower
bound for the typical time scale of growth (see Fig. 6). Nevertheless, in Fig. 7, we see that τ2 can
indeed act as an indicator for the onset of decay for the monomer mass. A more refined estimate
can be obtained by using the approximate solution for the full dynamics given in [12].
5 The case of a constant free monomer concentration
Another interesting case to consider is when the population of monomer is not depleted but remains
at a constant level m0. We assume that, regardless of other parameters, that (1) is instead specified
by
dp1
dt
= 0, (46)
so that, with unseeded initial conditions, we have p1(t) = m0 for all time. Assuming again no
depolymerization, no fragmentation, and dimer nucleation, the master equations now read
dp2
dt
= −λ2p2 + k0 + knm20 − 2k+m0p2 + k2σ0M, (47)
dpi
dt
= −λipi + 2k+m0(pi−1 − pi), i > 2, (48)
where σ0 = σ(m0) and M =
∑∞
i=2 ipi is the total toxic mass. This is an infinite system of linear
ordinary differential equations. For this system, we consider three types of clearance; the size-
independent case in addition to two different size-dependent paradigms. All three clearance relations
can be summarily presented by a power-law of the form
λi = λi
ν . (49)
When ν = 0 we recover the size-independent case; when ν = −1 we recover the size-dependent
diminishing clearance formulation used in Sec. 4; and, finally, the case of ν = 1 corresponds to
improved clearance, with increasing size, which could arise due to, for instance, antibody binding.
Depending on the two parameters λ and ν, the solution to this system may have a steady state
or increase indefinitely. The question is then to identify the critical values at which this transition
happens.
5.1 A constant free monomer population with constant clearance
We start with the simple case of constant clearance ν = 0; this is the analogue to Sec. 3 for a
constant free monomer assumption (c.f. (46)) The moments (c.f. Sec 3) are specified by a simple
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pair of linear equations given by
dP
dt
= − λP + k0 + knm20 + k2 σ0M, (50)
dM
dt
= − λM + 2k0 + 2k+mP + 2knm20 + 2k2 σ0M, (51)
which can be written as
q˙ = Aq+ b, (52)
where q = (P,M)T, b = (k0 + knm20, 2k0 + 2knm20)T and
A =
( −λ a
b 2a− λ
)
=
( −λ k2σ0
2k+m0 2k2σ0 − λ
)
. (53)
The constant solution sole steady state for this system is q∞ = −A−1b; q∞ is positive and finite if
λ > a+
√
a2 + ab = k2σ0 +
√
k22σ
2
0 + 2k2σ0k+m0 = λ
(0)
crit. (54)
This condition naturally provides a value for the critical clearance. Specifically, the largest linear
eigenvalue for the system is κ = λ(0)crit−λ; solutions converge to q∞ exponentially in time (as eκt) for
λ > λ
(0)
crit and grow unbounded for λ ≤ λ(0)crit. The values given in Table 1 for the different parameters
show that this estimate is indistinguishable from the case studied in Section 3, which is explained
by the fact that at the bifurcation point, the monomer population is constant in both cases.
5.2 A constant free monomer population with non-constant clearance
We now turn our attention to the general case where the clearance terms are not constant. Then, the
master equations do not yield a closed system for the moments. Nevertheless, due to the simplicity
introduced by p1(t) = m0 being constant, we can find conditions for the existence of a fixed-point
solution, (p∗2, p∗3, . . . ) to (47)-(48). If such a steady state p∗i for i > 2, exists, it must satisfy the
recurrence relation
p∗i = δip
∗
i−1, δi =
b
b+ λi
=
2k+m0
2k+m0 + λi
. (55)
we note that each of the recursion coefficients, δi, is now dependent on i via λi. Define a sequence
of real numbers, indexed by i, as
∆i =
i∏
j=3
δj , i > 2. (56)
We define ∆2 = 1 and the ith steady state is expressible, for all i ≥ 2, through its recurrence relation
as
p∗i = ∆ip
∗
2, i ≥ 2. (57)
Defining
∆ =
∞∑
j=3
∆j , (58)
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the steady state for the total toxic mass solution M∗ is then given by
M∗ =
∞∑
i=2
i∆ip
∗
2 = ∆p
∗
2, (59)
and an application of (47), at steady state, gives the value of p∗2 as
p∗2 =
k0 + knm
2
0
λ2 + 2k+m0 − k2σ0∆ . (60)
Therefore, for a fixed point to exist we need the three following conditions to be satisfied
C1: lim
i→∞
∆i = 0, (61)
C2: ∆ =
∞∑
i=2
i∆i converges, (62)
C3: k2σ0∆− λ2 − 2k+m0 > 0. (63)
An analysis of the case ν = 0 recovers the previous condition and it can then be verified directly
that conditions C1-C3 are satisfied, as expected, for λ > λ(0)crit.
5.2.1 Enhanced clearance: ν = 1
For ν = 1, we have (see Appendix C), ∆(1) = 2+b/λ and the steady population of dimers, whenever
it exists, is given by
p∗2 =
λ(k0 − knm20)
2(k+m0 + λ)(λ− k2σ0) . (64)
Hence, condition C3 leads to λ > λ(1)crit with
λ
(1)
crit = k2σ0. (65)
We note that the above implies that the critical clearance depends only on the secondary nucleation
process and, in particular, not the process of elongation (c.f. λ(0)crit in (54)).
5.2.2 Reduced clearance: ν = −1
For ν = −1, the situation is not as simple. The condition C1 is verified but C2 leads to λ > 2b for
which
∆(−1) =
(λ+ 2b)
(
Γ
(
λ
b − 2
)
Γ
(
λ
b + 2
)− Γ (λb )2)
2bΓ
(
λ
b
)2 , (66)
where Γ(·) is the usual Gamma function. Condition C3 is satisfied if λ > λ(−1)crit where λ(−1)crit is the
positive solution of
f(
λ
b
) = 1 +
2k+m0
k2σ0
, with f(
λ
b
) =
Γ
(
λ
b − 2
)
Γ
(
λ
b + 2
)
Γ
(
λ
b
)2 . (67)
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This equation always has a solution as f : z ∈ [2,∞] → f(z) is such that f ′(z) < 0, f(z)→z→2∞
and f(z) →z→∞ 1. For the parameters listed in Table 1, 2k+m0/k2σ0  1, in which case, we can
approximate the function f(z) close to z = 2 by f(z) ≈ 6/(z − 2), which leads to the critical value
λ
(−1)
crit =
8k+m0(2k2σ0 + k+m0)
k2σ0 + 2k+m0
(68)
This last relation can be further simplified by realizing that k+m0  k2σ0, which leads to
λ
(−1)
crit = 4k+m0. (69)
For the parameters given in Table 1, this last approximation of the critical clearance gives the
correct value (compared to (67)) to 6 digits. Note that, in contrast to the critical clearance rate
for enhanced clearance (c.f. (65)), (68) depends only on the elongation rate k+. In particular, in a
reduced clearance regime, a change in the rate of secondary nucleation has no effect on the clearance
rate required to keep the system stable. The general trend that can be observed from Table 1 is
that λ(−1)crit > λ
(0)
crit > λ
(1)
crit, as expected.
5.2.3 Further reduced clearance: ν = −2
Finally, for ν = −2, skipping computational details, we find that
lim
n→∞∆
(−2)
n =
1
4
pi
√
λ
b
((
λ
b
)2
+ 5
λ
b
+ 4
)
csch
(
pi
√
λ
b
)
, (70)
which is positive for all finite positive value of λ. Hence, condition C1 is not satisfied and there is
no constant solution or critical value of the clearance that would limit unbounded growth of toxic
proteins. We note that we have neglected the effect of fragmentation. For ν < 0, the effect of
fragmention is the creation of smaller aggregates that increase the overall expansion of the protein
population but also boosts clearance. Indeed since smaller aggregates are more likely to be cleared
and we expect a reduction of the critical value of clearance as well as the possibility of a finite value
of clearance for ν = −2 or smaller as shown in Meisl [27]. Comparing the different critical clearance
values given in Table 1 for the three values of ν, it is clear that that the choice of clearance law
has a significant impact on the clearance values as they differ, from the smallest to the largest by
9 orders of magnitude. Hence, enhancing or inhibiting the clearance mechanism may be extremely
important to the overall increase of toxic proteins.
6 Conclusion
We have assessed the impacts of production and clearance on the aggregation kinetics using a
theoretical model, c.f. (1)-(3), that has been experimentally validated [8, 15, 16]. Our findings
suggest that clearance may mediate toxic aggregation kinetics. In the case of constant clearance,
we showedthat toxic aggregation is controlled, directly, by a critical clearance. Clearance above this
level provides for a robust environment which is, essentially, free of toxic proteins; clearance below
this level triggers and instability and a propensity towards toxic mass accumulation. Once toxic
aggregation is triggered, the healthy monomer population is diminished as aggregates form. The
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maximal amount of toxic formation is, again, mediated by the clearance level; an effect of the mass
conservation principle, of this regime.
A reasonable in vivo hypothesis is that the clearance may depend on the aggregates size i.
This clearance paradigm has been explored using a simple inverse proportionality law λi = λ/i.
The resulting set of equations, for this type of clearance, does not yield a finite system for the
moments; thus, a super-particle system, with identical trajectories in the presence of unseeded initial
conditions, has been advanced as a means of study. In the presence of any aggregation effects,
the system immediately begins accumulating toxic mass; even from unseeded initial conditions.
Moreover, mass is not conserved and the toxic mass grows unboundedly in time. The clearance,
however, determines the asymptotic rate of increase of the toxic mass as a function of time with
M(t) ∼ λm0t. The biological implications of a size-dependent clearance are quite different than the
constant case. In particular, if clearance is size-dependent, results suggest that we have no recourse
in halting aggregate pathology through enhancing clearance; rather, we can only hope to delay the
overall trend of toxic accumulation.
The theoretical model of a constant free-monomer concentration was also consdired. This case is
particularly interesting since, under the assumption of steady states, we see that a notion of critical
clearance can be established for relations of the form λi = λiν for ν ∈ {−1, 0, 1}. In the case of
ν = 0, we recover the previous results given for constant clearance. Similarly, in the size-dependent
case (ν = −1 and ν = 1), there exists a critical value of the clearance so that no aggregation
takes place past that value. Remarkably, our results suggest that, depending on the specific size-
dependence, the processes of elongation and secondary nucleation contribute to the value of the
critical clearance to different degrees. An important implication is that, depending on the specific
mechanism of clearance, inhibition of aggregation should target different processes in order to reduce
the critical clearance rate.
Overall, the role of clearance in aggregation kinetics is highly non-trivial. However, our study
shows that clearance may play an important role in the aggregation kinetics of Amyloid-β and that
additional experiments, providing fitted values for clearance parameters, would serve to elucidate
appropriate regimes for further study.
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A Normal form for a transcritical bifurcation
Here we derive the normal form of a transcritical for a general dynamical system. We consider an
autonomous n-dimensional C2 vector field of the form
x˙ = f(x, λ), x ∈ Rn, (71)
and assume that there exists a constant solution x0 such that f(x0, λ) = 0 and a different equilibrium
solution in a neighborhood of the critical value λ0. The conditions for the existence of a transcritical
bifurcation at the critical value λ0 are given by Sotomayor’s theorem [21] and the reduced form the
system takes close to that value can be captured by normal form theory [22, 23, 24, 25]. Here, we
use multiple scale analysis to obtain a convenient form of the reduced equations. The result in itself
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is not original but it may not be obvious to find a direct reference for either the statement or the
proof. Therefore, its inclusion may be helpful to the reader.
Using multiple-scale expansion, we expand the solution as
x = x0 + x1 + 
2 x2 + . . . , λ = λ0 + λ1. (72)
where x0 is constant and xi = xi(t, τ), i>1 and τ = t is a slow time [26]. The expansion of the
vector field close to second order is
f = f0 (73)
+  [Df0 · x1 + fλ,0λ1] (74)
+ 2
[
Df0 · x2 + 1
2
Hf0(x1,x1) + λ1Dfλ,0 · · ·x1
]
(75)
+ . . . , (76)
where f0 = f(x0, λ0) indicates that f is evaluated at the point (x0, λ0) and
(Df)ij =
∂fi
∂xj
, Df0 = Df(x0, λ0), (77)
fλ =
∂f
∂λ
, fλ,0 = fλ(x0, λ0), (78)
(Hf)ijk =
∂2fi
∂xj∂xk
, Hf0 = Hf(x0, λ0), (79)
(Dfλ)ij =
∂2fi
∂xj∂λ
, Dfλ,0 = Dfλ(x0, λ0). (80)
If the system has a bifurcation of co-dimension one at λ0 then Df0 has rank n− 1 and the following
vectors w and v given by
w ·Df0 = 0, Df0 · v = 0, (81)
define the left and right null spaces of Df0. The generic condition for a transcritical bifurcation to
occur is
w · fλ,0 = 0. (82)
To order O(), the differential equation reads
x˙1 = Df0 · x1 + λ1fλ,0. (83)
and we are interested in the solution
x1 = c(τ)v, (84)
whose existence is guaranteed by the condition w · fλ,0 = 0. To second order O(2), we have
x˙2 + c
′(τ)v = Df0 · x2 + c2 1
2
Hf0(v,v) + cλ1Dfλ,0 · v. (85)
The Fredholm alternative gives a condition for the existence of a solution of this inhomogeneous
system:
w · (c′(τ)v) = w ·
(
c2
1
2
Hf0(v,v) + cλ1Dfλ,0 · v
)
, (86)
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which gives the equation
c′(τ) = βλ1c+ αc2, (87)
where
α =
1
2
1
v ·w w ·Hf0(v,v) (88)
β =
1
v ·w w ·Dfλ,0 · v. (89)
Taking into account that λ1 = λ− λ0 and defining y = c, the local solution is x = x0 + yv where
y˙ = β(λ− λ0)y + αy2, (90)
is the normal form of a transcritical bifurcation at λ = λ0. The local evolution of the variables for
which vi 6= 0 is given by
x˙i = β(λ− λ0)(xi − x0,i) + α
vi
(xi − x0,i)2. (91)
B Mass balance in the size-dependent clearance case
For unseeded initial conditions, we can show that the total mass of the system is not conserved.
Assume that, for all 2 ≤ i we have λi ≤ λ1 and assume that there exists some index j, with 2 ≤ j,
such that the inequality is strict (i.e. λj < λ1). In this case we have
dM˜
dt
> −λ1
N−1∑
i=2
ipi + 2k0 + 2knp
2
1 + 2k+p1P + 2k2 σ(p1)M˜
> −λ1
∞∑
i=2
ipi + 2k0 + 2knp
2
1 + 2k+p1P + 2k2 σ(p1)M˜
= −λ1M˜ + 2k0 + 2knp21 + 2k+p1P + 2k2 σ(p1)M˜. (92)
Likewise for i = 2 we have a similar inequality
dp2
dt
= −λ2 p2 + k0 + knp21 − 2k+p1p2 + k2σ(p1)M˜,
> −λ1 p2 + k0 + knp21 − 2k+p1p2 + k2σ(p1)M˜, (93)
and likewise for i > 2. The above observation shows that the system (26)-(29) grows faster than the
constant-clearance case system where λi = λ1 for every i ∈ {1, 2, . . . }. We note that, as in Sec. 3,
the total system mass for (26)-(29) is M˜tot = M˜ + p1; this follows from the common definition of
M˜ , here, and M (see (4)). Adding (26) to (27) and using (92) gives
dM˜tot
dt
> λ1
(
m0 − M˜tot
)
. (94)
In the presence of the unseeded initial conditions (30) we have that M˜tot(0) = m0 so that the
left-hand side of (94) is strictly positive and mass conservation is violated at the outset. Now let
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Mλ1tot denote the total mass of the constant clearance case λi = λ1 for all i. We know that, in the
presence of unseeded initial conditions, a sysetm with constant clearance systems conserves mass
so that
dMλ1tot
dt
= 0.
From (92) and (93), which holds analagously for i > 2 and for i = 1 we have equality, we can
conclude that
dM˜tot
dt
≥ dM
λ1
tot
dt
= 0, (95)
for unseeded initial conditions. Take together, (94) implies that the system (26)-(29), with unseeded
initial conditions, initially gains mass while (95) shows that it can never lose mass. Therefore, not
only does (26)-(29) not conserve mass but it can never return to the state of initial unseeded mass.
C Critical value for enhanced clearance
For ν = 1, the case (56) takes the form
∆i =
i∏
m=3
(
b
b+mλ
)
=
(b+ λ)(b+ 2λ)
b2
(
b
λ
)i((b+ λ
λ
)
i
)−1
, i ≥ 3, (96)
where the subscript (x)i = x(x + 1)(x + 2) · · · (x + i − 1) denotes ascending factorial (i.e. the
Pochhammer symbol). Defining ξ = bλ−1 then (C1) is satisfied provided
lim
i→∞
ξi
(ξ + 1)i
= 0. (97)
The function ξi((ξ+1)i)−1 is monotonically decreasing in both ξ and i and condition C1 is satisfied
for any ξ > 0. Using ξ = bλ−1 the expression (96) implies
∆(1) = 2 +
(λ+ λξ)(2λ+ λξ)
λ2ξ2
∞∑
i=3
i
ξi
(ξ + 1)i
= 2 +
(λ+ λξ)(2λ+ λξ)
λ2ξ2
(
ξ3
2 + 3ξ + ξ2
)
= 2 + ξ.
Thus we have
∆(1) = 2 +
b
λ
, (98)
and it follows that p∗2, for ν = 1, is determined by the formula
p∗2 =
λ(k0 − knm20)
2(k+m0 + λ)(λ− k2σ0) . (99)
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